Thiazolopyrimidine

Thiazolopyrimidine

SCHEMBL1703410

Nc1nc2nc(N)sc2c(=O)[nH]1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.52
CXCR2 P25025 4/20 0.50
PNP P00491 2/20 0.50
CXCR1 P25024 1/20 0.50
THRB P10828 2/20 0.44
MITF O75030 1/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
HBB P68871 1/20 0.44
HIF1A Q16665 1/20 0.44
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP1A2 P05177 1/20 0.39
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4570271 0.81 PNP (0.47) RPS6KA3CXCR2PNPCXCR1THRB
SCHEMBL8435574 0.81 PNP (0.47) RPS6KA3CXCR2PNPCXCR1THRB
SCHEMBL9151696 0.69 KDM4E (0.50) CXCR2PNPTHRBMITFTP53
SCHEMBL26155928 0.69 ALDH1A1 (0.45) RPS6KA3CXCR2PNPCXCR1MAPT
SCHEMBL654655 0.68 MITF (0.44) RPS6KA3PNPTHRBMITFTP53
SCHEMBL338384 0.68 RPS6KA3 (0.52) RPS6KA3PNPTHRBMITFTP53
SCHEMBL3755970 0.68 RPS6KA3 (1.00) RPS6KA3CXCR2PNPCXCR1MAPT
SCHEMBL8437718 0.67 CXCR1 (0.45) CXCR2PNPCXCR1
SCHEMBL8435033 0.67 CXCR2 (0.45) CXCR2PNPCXCR1THRBMITF
8-Aminoguanine SCHEMBL21761 0.67 PNP (1.00) PNPTHRBMITFTP53ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220211710-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH NUCLEOSIDE-METABOLISM MODULATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-07-07 US disclosed
US-9993491-B2 Guanine riboswitch binding compounds and their use as antibiotics SOCPRA—SCIENCES ET GÉNIE S.E.C. (CA) 2018-06-12 US disclosed
EP-2440533-B1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS SOCPRA SCIENCES ET GÉNIE S E C (CA) 2015-09-23 EP disclosed
US-20150150890-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS UNIVERSITE DE SHERBROOKE (CA) 2015-06-04 US disclosed
US-20120122819-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS SOCPRA - SCIENCES ET GENIE S.E.C. (CA) 2012-05-17 US disclosed
EP-2440533-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS Socpra-Sciences Et Génie S.E.C. (CA) 2012-04-18 EP disclosed
WO-2010142027-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS SOCPRA - SCIENCES ET GENIE S. E. C. (CA) 2010-12-16 WO disclosed
US-6562969-B1 Ricin A-chain is an N-glycosidase that attacks ribosomal RNA at a highly conserved adenine residue. Crystallographic studies show that not only adenine and formycin, but also pterin-based rings can bind in the ricin active site. RESEARCH DEVELOPMENT FOUNDATION 2003-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150890-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS GDA, RNMT, GNPDA1 RPS6KA3 2111/4885CXCR2 2597/4885PNP 618/4885
US-20120122819-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS GDA, RNMT, GNPDA1 RPS6KA3 2111/4885CXCR2 2597/4885PNP 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.